HD-OPM Archive
Topics › PCSK9, ezetimibe & newer drugs

FDA approves inclisiran (Leqvio) for first-line use, with two doses a year

Gokhan Can · Aug 05, 2025 · ♥ 14 reactions · 9 comments · original Facebook post
PCSK9, ezetimibe & newer drugsLDL, ApoB & lipid panel
AI summary & key facts

News that the FDA broadened inclisiran's approval so it can be used first-line, lowering LDL with two injections a year. No trial data are discussed in the post.

The FDA just updated the approval for Inclisiran—a small-interfering RNA therapy for cholesterol—by making it a front-line therapy.

Now, with just two shots a year rather than with daily statin dosing you can lower your LDL.

Novartis United States of AmericaNovartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line usenovartis.com

Research cited

#cholesterol#statins
← newer: Cheese umbrella review: modestly lower mortality, CVD, strokolder: Metformin's glucose lowering is regulated by Rap1 in brain n →